CEPHEID (CPHD) Shares are Up 7.58%

CEPHEID (CPHD) : Traders are bullish on CEPHEID (CPHD) as it has outperformed the S&P 500 by a wide margin of 2.99% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.65%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.58% in the last 1 week, and is up 6.45% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 8.17% and the 50-Day Moving Average is 17.17%. Cepheid is up 23.79% in the last 3-month period. Year-to-Date the stock performance stands at -3.28%.


CEPHEID (NASDAQ:CPHD): stock turned positive on Friday. Though the stock opened at $35.13, the bulls momentum made the stock top out at $37.1 level for the day. The stock recorded a low of $33.27 and closed the trading day at $35.33, in the green by 8.04%. The total traded volume for the day was 2,918,067. The stock had closed at $32.7 in the previous days trading.

Also, Major Brokerage house, JP Morgan maintains its ratings on CEPHEID (NASDAQ:CPHD). In the latest research report, JP Morgan raises the target price from $32 per share to $35 per share. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on July 29, 2016.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.